ONCAlert | Upfront Therapy for mRCC

Hematology VIEW MORE >>

The FDA has granted Priority Review to the New Drug Application for tazemetostat as treatment for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy. The drug will now be considered for accelerated approval and the application was designation as a supplemental NDA with a Prescription Drug User Fee Act target action date of June 18, 2020, Epizyme, Inc announced in a press release.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.